TCR2 Therapeutics (TCRR) PT Raised to $45 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
TCR² Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors
July 26, 2020 5:01 PM EDT- TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients
- Two RECIST unconfirmed partial responses and two patients with stable disease through six months
      - Manageable toxicity profile, with only one patient exhibiting TC-210-related non-hematologic Grade >2 toxicity
      - Translational data demonstrated T cell expansion and cytokine production
- TCR2 to host conference call today starting at 8:00am E.T. with live webcast available online
CAMBRIDGE, Mass., July 26, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq:... More
TCR² Therapeutics to Announce Interim Data from Phase 1/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors
July 24, 2020 4:06 PM EDTCAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company plans to discuss initial data from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors in a premarket press release and webcast to be held on Monday, July 27th, 2020.
The... More
